07 February 2024

Circular No. (856) for the year 2024 Lifting the Suspension on the Registration of the Pharmaceutical Product Azomax

Reference: CIR-2024-00000025

To all Health, facilities / all health care practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the Circular issued by the MOHAP for perusal and adhere to what is stated

 

Circular No. (856) for the year 2024 Lifting the Suspension on the Registration of the Pharmaceutical Product Azomax

 

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

Azomax 250 mg capsule - رفع تعليق عن تسجيل المنتج الطبي ----.pdf:

View Document